v3.26.1
CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Veraxa Biotech A G [Member] - CHF (SFr)
Dec. 31, 2025
Dec. 31, 2024
ASSETS    
Property and equipment, net SFr 1,984,977 SFr 1,961,792
Goodwill 22,848,728 22,848,728
Intangible assets, net 51,907,963 53,485,292
Right-of-Use lease assets 1,123,395 864,486
Other receivables - Long term 70,718
Total non-current assets 77,935,781 79,160,298
Other receivables 1,111,424 153,606
Other receivables - related party 58,927 21,268
Prepaid expenses and other current assets 100,243 68,814
Cash and cash equivalents 1,613,989 5,362,638
Total current assets 2,884,583 5,606,326
Total Assets 80,820,364 84,766,624
Equity    
Subscribed capital 14,751,067 14,182,189
Capital reserve 68,252,651 48,959,480
Other reserve (291,525) (222,503)
Accumulated deficit (98,478,340) (31,864,350)
Total shareholder’s deficit (15,766,147) 31,054,816
Noncurrent lease liabilities 883,553 708,082
Deferred tax liabilities 14,440,732 15,165,086
Contingent liabilities 2,898,873 2,099,705
Remuneration commitments (SARs) 71,749,543 33,192,793
Total non-current liabilities 89,972,701 51,165,666
Accounts payable 1,390,932 488,543
Accrued expenses 2,675,623 1,802,350
Current lease liabilities 257,095 156,403
Notes payable - related parties 1,000,000
Other current liabilities 1,290,160 98,846
Total current liabilities 6,613,810 2,546,142
Total liabilities 96,586,511 53,711,808
TOTAL LIABILITIES AND EQUITY SFr 80,820,364 SFr 84,766,624